TY - JOUR AU - Tol, J. AU - Nagtegaal, I. PY - 2009 DA - 2009// TI - Punt C.BRAF mutation in metastatic colorectal cancer JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMc0904160 DO - 10.1056/NEJMc0904160 ID - Tol2009 ER - TY - STD TI - Cantwell-Dorris ER, O’Leary JJ, Sheils OM.BRAF V600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385–94. ID - ref2 ER - TY - JOUR AU - Yaeger, R. AU - Cercek, A. AU - Chou, J. F. AU - Sylvester, B. E. AU - Kemeny, N. E. AU - Hechtman, J. F. PY - 2014 DA - 2014// TI - BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer JO - Cancer VL - 120 UR - https://doi.org/10.1002/cncr.28729 DO - 10.1002/cncr.28729 ID - Yaeger2014 ER - TY - JOUR AU - Samowitz, W. S. AU - Sweeney, C. AU - Herrick, J. AU - Albertsen, H. AU - Levin, T. R. AU - Murtaugh, M. A. PY - 2005 DA - 2005// TI - Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-0404 DO - 10.1158/0008-5472.CAN-05-0404 ID - Samowitz2005 ER - TY - JOUR AU - Richman, S. D. AU - Seymour, M. T. AU - Chambers, P. AU - Elliott, F. AU - Daly, C. L. AU - Meade, A. M. PY - 2009 DA - 2009// TI - KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.22.4295 DO - 10.1200/JCO.2009.22.4295 ID - Richman2009 ER - TY - JOUR AU - Heinemann, V. AU - Weikersthal, L. F. AU - Decker, T. AU - Kiani, A. AU - Vehling-Kaiser, U. AU - Al-Batran, S. E. PY - 2014 DA - 2014// TI - FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70330-4 DO - 10.1016/S1470-2045(14)70330-4 ID - Heinemann2014 ER - TY - JOUR AU - Douillard, J. Y. AU - Oliner, K. S. AU - Siena, S. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2013 DA - 2013// TI - Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305275 DO - 10.1056/NEJMoa1305275 ID - Douillard2013 ER - TY - STD TI - COSMIC: Catalogue of Somatic Mutation in Cancer. Gene variants for BRAF. http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF Accessed 31 Mar 2017. UR - http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF ID - ref8 ER - TY - JOUR AU - Mori, Y. AU - Nagasaka, T. AU - Mishima, H. AU - Umeda, Y. AU - Inada, R. AU - Kishimoto, H. PY - 2015 DA - 2015// TI - The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma—a report of a case JO - BMC Med Genet VL - 16 UR - https://doi.org/10.1186/s12881-015-0144-7 DO - 10.1186/s12881-015-0144-7 ID - Mori2015 ER - TY - JOUR AU - Amaki-Takao, M. AU - Yamaguchi, T. AU - Natsume, S. AU - Iijima, T. AU - Wakaume, R. AU - Takahashi, K. PY - 2016 DA - 2016// TI - Colorectal cancer with BRAF D594G mutation is not associated with microsatellite instability or poor prognosis JO - Oncology. VL - 91 UR - https://doi.org/10.1159/000447402 DO - 10.1159/000447402 ID - Amaki-Takao2016 ER - TY - JOUR AU - Cremolini, C. AU - Bartolomeo, M. D. AU - Amatu, A. AU - Antoniotti, C. AU - Moretto, R. AU - Berenato, R. PY - 2015 DA - 2015// TI - BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv290 DO - 10.1093/annonc/mdv290 ID - Cremolini2015 ER - TY - JOUR AU - Cutsem, E. AU - Cervantes, A. AU - Adam, R. AU - Sobrero, A. AU - Krieken, J. H. AU - Aderka, D. PY - 2016 DA - 2016// TI - ESMO consensus guidelines for the management of patients with metastatic colorectal cancer JO - Ann Oncol. VL - 27 UR - https://doi.org/10.1093/annonc/mdw235 DO - 10.1093/annonc/mdw235 ID - Cutsem2016 ER - TY - JOUR AU - Souglakos, J. AU - Philips, J. AU - Wang, R. AU - Marwah, S. AU - Silver, M. AU - Tzardi, M. PY - 2009 DA - 2009// TI - Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer JO - Br J Cancer VL - 101 UR - https://doi.org/10.1038/sj.bjc.6605164 DO - 10.1038/sj.bjc.6605164 ID - Souglakos2009 ER - TY - JOUR AU - Bokemeyer, C. AU - Cutsem, E. AU - Rougier, P. AU - Ciardiello, F. AU - Heeger, S. AU - Schlichting, M. PY - 2012 DA - 2012// TI - Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2012.02.057 DO - 10.1016/j.ejca.2012.02.057 ID - Bokemeyer2012 ER - TY - JOUR AU - Loupakis, F. AU - Cremolini, C. AU - Salvatore, L. AU - Masi, G. AU - Sensi, E. AU - Schirripa, M. PY - 2014 DA - 2014// TI - FOLFOXIRI plus bevacizumab as first-line treatment in BRAF, mutant metastatic colorectal cancer JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2013.08.024 DO - 10.1016/j.ejca.2013.08.024 ID - Loupakis2014 ER - TY - JOUR AU - Cremolini, C. AU - Loupakis, F. AU - Antoniotti, C. AU - Lupi, C. AU - Sensi, E. AU - Lonardi, S. PY - 2015 DA - 2015// TI - FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00122-9 DO - 10.1016/S1470-2045(15)00122-9 ID - Cremolini2015 ER - TY - JOUR AU - Mellas, N. AU - Benbrahim, Z. AU - Mesbahi, O. PY - 2014 DA - 2014// TI - Colorectal cancer: new developments after the 2013 ECCO/ESMO congress JO - Chin J Cancer. VL - 33 ID - Mellas2014 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Giantonio, B. J. AU - Catalano, P. J. AU - Meropol, N. J. AU - O’Dwyer, P. J. AU - Mitchell, E. P. AU - Alberts, S. R. PY - 2007 DA - 2007// TI - Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.6305 DO - 10.1200/JCO.2006.09.6305 ID - Giantonio2007 ER - TY - JOUR AU - Caprioni, F. AU - Fornarini, G. PY - 2007 DA - 2007// TI - Bevacizumab in the treatment of metastatic colorectal cancer JO - Future Oncol. VL - 3 UR - https://doi.org/10.2217/14796694.3.2.141 DO - 10.2217/14796694.3.2.141 ID - Caprioni2007 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: colon cancer (2017.V1)[EB/OL]. (2016-11-23) [2016-12-22]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. UR - https://www.nccn.org/professionals/physician_gls/f_guidelines.asp ID - ref21 ER - TY - JOUR AU - Wei, Q. AU - Wang, X. AU - Gao, J. AU - Li, J. AU - Li, J. AU - Qi, C. PY - 2016 DA - 2016// TI - Clinicopathologic and molecular features of colorectal adenocarcinoma with signet-ring cell component JO - PLoS ONE VL - 11 UR - https://doi.org/10.1371/journal.pone.0156659 DO - 10.1371/journal.pone.0156659 ID - Wei2016 ER - TY - JOUR AU - Tran, B. AU - Kopetz, S. AU - Tie, J. AU - Gibbs, P. AU - Jiang, Z. Q. AU - Lieu, C. H. PY - 2011 DA - 2011// TI - Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.26086 DO - 10.1002/cncr.26086 ID - Tran2011 ER - TY - JOUR AU - Tie, J. AU - Gibbs, P. AU - Lipton, L. AU - Christie, M. AU - Jorissen, R. N. AU - Burgess, A. W. PY - 2011 DA - 2011// TI - Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation JO - Int J Cancer VL - 128 UR - https://doi.org/10.1002/ijc.25555 DO - 10.1002/ijc.25555 ID - Tie2011 ER - TY - JOUR AU - Mao, M. AU - Tian, F. AU - Mariadason, J. T. AU - Tsao, C. C. AU - Lemos, R. J. AU - Dayyani, F. PY - 2013 DA - 2013// TI - Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-11-1446 DO - 10.1158/1078-0432.CCR-11-1446 ID - Mao2013 ER - TY - JOUR AU - Coffee, E. M. AU - Faber, A. C. AU - Roper, J. AU - Sinnamon, M. J. AU - Goel, G. AU - Keung, L. PY - 2013 DA - 2013// TI - Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2556 DO - 10.1158/1078-0432.CCR-12-2556 ID - Coffee2013 ER - TY - JOUR AU - Yaeger, R. AU - Cercek, A. AU - O’Reilly, E. M. AU - Reidy, D. L. AU - Kemeny, N. AU - Wolinsky, T. PY - 2015 DA - 2015// TI - Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2779 DO - 10.1158/1078-0432.CCR-14-2779 ID - Yaeger2015 ER - TY - JOUR AU - Barras, D. AU - Missiaglia, E. AU - Wirapati, P. AU - Sieber, O. M. AU - Jorissen, R. N. AU - Love, C. PY - 2017 DA - 2017// TI - BRAF V600E mutant colorectal cancer subtypes based on gene expression JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0140 DO - 10.1158/1078-0432.CCR-16-0140 ID - Barras2017 ER -